The First Cell

Home > Other > The First Cell > Page 32
The First Cell Page 32

by Azra Raza


  Bak, Per. How Nature Works. Oxford, UK: Oxford University Press, 1996.

  Weinberg, R. One Renegade Cell: The Quest for the Origins of Cancer. New York: Basic Books, 1998.

  Mehta, Suketu. “Fire in the Belly: A Batch of Chili Proves Life-Affirming in More Ways Than One.” Saveur, September 27, 2010. www.saveur.com/article/Kitchen/Fire-in-the-Belly.

  Gibbs, W. Wayt. “Untangling the Roots of Cancer.” Scientific American, July 1, 2008. www.scientificamerican.com/article/untangling-the-roots-of-cancer-2008-07/.

  Weinberg, Robert. “How Cancer Arises.” Scientific American, September 1996. https://courses.washington.edu/gs466/readings/Weinberg.pdf.

  Mukherjee, Siddhartha. The Emperor of All Maladies: A Biography of Cancer. New York: Scribner, 2010.

  Danaei, G., S. Vander Hoorn, A. D. Lopez, C. J. Murray, and M. Ezzati. “Comparative Risk Assessment Collaborating Group (Cancers). Causes of Cancer in the World: Comparative Risk Assessment of Nine Behavioural and Environmental Risk Factors.” Lancet 366, no. 9499 (2005): 1784–1793.

  Mukherjee, Siddhartha. The Gene: An Intimate History. New York: Scribner, 2016.

  zur Hausen, H. “Condylomata Acuminata and Human Genital Cancer.” Cancer Research 36, no. 794 (1976).

  Poiesz, B. J., F. W. Ruscetti, A. F. Gazdar, P. A. Bunn, J. D. Minna, and R. C. Gallo. “Detection and Isolation of Type C Retrovirus Particles from Fresh and Cultured Lymphocytes of a Patient with Cutaneous T-Cell Lymphoma.” Proceedings of the National Academy of Sciences of the United States of America 77, no. 12 (1980): 7415–7419.

  Gallo, R. C. “History of the Discoveries of the First Human Retroviruses: HTLV-1 and HTLV-2.” Oncogene 24 (2005): 5926–5930.

  Moore, Patrick S., and Yuan Chang. “Why Do Viruses Cause Cancer? Highlights of the First Century of Human Tumour Virology.” Nature Reviews Cancer 10 (2010): 878–889.

  Sansregret, Laurent, and Charles Swanton. “The Role of Aneuploidy in Cancer Evolution.” Cold Spring Harbor Perspectives in Medicine. Published in advance, October 21, 2016. doi:10.1101/cshperspect.a028373.

  Rous, P. “A Sarcoma of the Fowl Transmissible by an Agent Separable from the Tumor Cells.” Journal of Experimental Medicine 13, no. 4 (1911): 397–399.

  Rous, Peyton. “The Challenge to Man of the Neoplastic Cell.” Nobel lecture, December 13, 1966. www.nobelprize.org/prizes/medicine/1966/rous/lecture/.

  Kumar, Prasanna, and Frederick A. Murphy. “Francis Peyton Rous.” Emerging Infectious Diseases 19, no. 4 (2013): 660–663. www.ncbi.nlm.nih.gov/pmc/articles/PMC3647430/.

  Rubin, H. “The Early History of Tumor Virology: Rous, RIF, and RAV.” Proceedings of the National Academy of Sciences of the United States of America 108 (2011): 14389–14396.

  Weiss, R. A., and P. K. Vogt. “100 Years of Rous Sarcoma Virus.” Journal of Experimental Medicine 208 (2011): 2351–2355.

  Burkitt, D. “A Sarcoma Involving the Jaws in African Children.” British Journal of Surgery 46, no. 197 (1958): 218–223.

  Smith, Emma. “50 Years of Epstein-Barr Virus.” Cancer Research UK. https:// scienceblog.cancerresearchuk.org/2014/03/26/50-years-of-epstein-barr-virus/.

  Javier, Ronald T., and Janet S. Butel. “The History of Tumor Virology.” Cancer Research 68, no. 19 (2008): 7693–7706.

  Bister, Klaus. “Discovery of Oncogenes: The Advent of Molecular Cancer Research.” Proceedings of the National Academy of Sciences of the United States of America 112, no. 50 (2015): 15259–15260.

  Lane, D., and A. Levine. “p53 Research: The Past 30 Years and the Next 30 Years.” Cold Spring Harbor Perspectives in Biology 2, no. 12 (2010): a000893. doi:10.1101/cshperspect.a000893.

  Donehower, Lawrence A. “Using Mice to Examine p53 Functions in Cancer, Aging, and Longevity.” Cold Spring Harbor Perspectives in Biology 1, no. 6 (2009): a001081.

  Lane, David P., Chit Fang Cheok, and Sonia Lain. “p53-Based Cancer Therapy.” Cold Spring Harbor Perspectives in Biology 2, no. 9 (2010): a001222. doi:10.1101/cshperspect.a001222.

  Bieging, Kathryn T., Stephano Spano Mello, and Laura D. Attardi. “Unravelling Mechanisms of p53-Mediated Tumour Suppression.” Nature Reviews Cancer 14 (2014): 359–370.

  Li, F. P., and J. F. Fraumeni. “Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms: A Familial Syndrome?” Annals of Internal Medicine 71, no. 4 (1969): 747–752.

  Hisada, M., J. E. Garber, F. P. Li, C. Y. Fung, and J. F. Fraumeni. “Multiple Primary Cancers in Families with Li-Fraumeni Syndrome.” Journal of the National Cancer Institute 90, no. 8 (1998): 606–611.

  Birch, J. M., A. L. Hartley, K. Tricker, J. Prosser, A. Condie, A. Kelsey, et al. “Prevalence and Diversity of Constitutional Mutations in the p53 Gene Among 21 Li-Fraumeni Families.” Cancer Research 54, no. 5 (1994): 1298–1304.

  Greicius, Julie. “And Yet, You Try: A Father’s Quest to Save His Son.” Stanford Medicine: Diagnostics, Fall 2016. https://stanmed.stanford.edu/2016fall/milan-gambhirs-li-fraumeni-syndrome.html.

  Haase, Detlef. “TP53 Mutation Status Divides Myelodysplastic Syndromes with Complex Karyotypes into Distinct Prognostic Subgroups.” Nature, January 2019. www.nature.com/articles/s41375-018-0351-2.

  Martinez-Hoyer, Sergio, et al. “Mechanisms of Resistance to Lenalidomide in Del(5q) Myelodysplastic Syndrome Patients.” Blood 126 (2015): 5228.

  Abegglen, Lisa M., et al. “Potential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in Humans.” JAMA 314, no. 17 (2015): 1850–1860. doi:10.1001/jama.2015.13134.

  Caulin, Aleah F., and Carlo C. Maley. “Peto’s Paradox: Evolution’s Prescription for Cancer Prevention.” Trends in Ecology & Evolution 26, no. 4 (2011): 175–182. doi:10.1016/j.tree.2011.01.002.

  Tollis, Marc, Amy M. Boddy, and Carlo C. Maley. “Paradox: How Has Evolution Solved the Problem of Cancer Prevention?” BMC Biology 15, no. 60 (2017).

  Callaway, Ewen. “How Elephants Avoid Cancer: Pachyderms Have Extra Copies of a Key Tumour-Fighting Gene.” Nature, October 8, 2015.

  Armstrong, Susan. P53: The Gene That Cracked the Cancer Code. New York: Bloomsbury Sigma, 2016.

  García-Cao, Isabel. “‘Super p53’ Mice Exhibit Enhanced DNA Damage Response, Are Tumor Resistant and Age Normally.” EMBO Journal 21, no. 22 (2002): 6225–6235.

  Hogenboom, Melissa. “The Animals That Don’t Get Cancer.” BBC, October 31, 2015. www.bbc.com/earth/story/20151031-the-animal-that-doesnt-get-cancer.

  Tomasetti, Cristian, Lu Li, and Bert Vogelstein. “Stem Cell Divisions, Somatic Mutations, Cancer Etiology, and Cancer Prevention.” Science 355, no. 331 (2017): 1330–1334.

  Vogelstein, Bert, Nickolas Papadopoulos, Victor E. Velculescu, Shibin Zhou, Luis A. Diaz, Jr., and Kenneth W. Kinzler. “Cancer Genome Landscapes.” Science 339, no. 6127 (2013): 1546–1558.

  “New Study Finds That Most Cancer Mutations Are Due to Random DNA Copying ‘Mistakes.’” Johns Hopkins Medicine, March 23, 2017. www.hopkinsmedicine.org/news/media/releases/new_study_finds_that_most_cancer_mutations_are_due_to_random_dna_copying_mistakes.

  Yachida, S., S. Jones, I. Bozic, T. Antal, R. Leary, B. Fu, M. Kamiyama, R. H. Hruban, J. R. Eshleman, M. A. Nowak, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, and C. A. Iacobuzio-Donahue. “Distant Metastasis Occurs Late During the Genetic Evolution of Pancreatic Cancer.” Nature 467 (2010): 1114–1117.

  Pienta, Ken, et al. “The Cancer Diaspora: Metastasis Beyond the Seed and Soil Hypothesis.” Clinical Cancer Research 19, no. 21 (2013). doi:10.1158/1078-0432.CCR-13-2158.

  McGranahan, Nicholas, and Charles Swanton. “Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.” Cell 168 (2017): 631.

  Giam, Maybelline, and Giulia Rancati. “Aneuploidy and Chromosomal Instability in Cancer: A Jackpot to Chaos.” Cell Division 10 (2015): 3. doi: 10.1186/s13008-015-0009-7.

  “How Well Do We Understand the Relation Between Incorrect Chromosome Number and Cancer?” EurekAlert! https://www.eurekalert.org/pub_releases/2017-01/cshl-hwd011117.php.

>   Sheltzer, J. M., et al. “Single-Chromosome Gains Commonly Function as Tumor Suppressors.” Cancer Cell 31, no. 2 (2017): 240–255. doi:10.1016/j.ccell.2016.12.004.

  Ansari, David. “Pancreatic Cancer and Thromboembolic Disease, 150 Years After Trousseau.” Hepatobiliary Surgery and Nutrition 4, no. 5 (2015): 325–335.

  Campisi, Judith. “Aging, Cellular Senescence, and Cancer.” Annual Review of Physiology 75 (2013): 685–705.

  Lee, Seongju, and Jae-Seon Lee. “Cellular Senescence: A Promising Strategy for Cancer Therapy.” BMB Reports 52, no. 1 (2019): 35–41.

  Lan, Wei, and Ying Miao. “Autophagy and Senescence.” Senescence Signalling and Control in Plants (2019): 239–253. https://doi.org/10.1016/B978-0-12-813187-9.00015-9.

  Franceschi, Claudio, and Judith Campisi. “Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases.” Journals of Gerontology: Series A 69, supplement 1 (2014): S4–S9.

  Harley, Calvin B., and Bryant Villeponteau. “Telomeres and Telomerase in Aging and Cancer.” Current Opinion in Genetics & Development 5, no. 2 (1995): 249–255.

  Blackburn, Elizabeth, and Elissa Epel. The Telomere Effect: A Revolutionary Approach to Living Younger, Healthier, Longer. New York: Grand Central Publishing, 2017.

  Steensma, D., et al. “Clonal Hematopoiesis of Indeterminate Potential and Its Distinction from Myelodysplastic Syndromes.” Blood 126 (2015): 9–16.

  Jaiswal, S., et al. “Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes.” New England Journal of Medicine 371 (2014): 2488–2498.

  Bertamini, L., et al. “Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Coronary Artery Disease and in Centenarians: Further Clues Linking CHIP with Cardiovascular Risk.” Blood 130 (2017): 1144.

  Thomas, Hugh. “Mutation and Clonal Selection in the Ageing Oesophagus.” Nature Reviews Gastroenterology & Hepatology 16 (2019): 139.

  Martincorena, I., et al. “Somatic Mutant Clones Colonize the Human Esophagus with Age.” Science 362 (2018): 911–917.

  Yokoyama, A., et al. “Age-Related Remodelling of Oesophageal Epithelia by Mutated Cancer Drivers.” Nature 565 (2019): 312–317.

  Malcovati, Luca, et al. “Clinical Significance of Somatic Mutation in Unexplained Blood Cytopenia.” Blood 129 (2017): 3371–3378.

  Fialkow, P. J., P. J. Martin, V. Najfeld, G. K. Penfold, R. J. Jacobson, and J. A. Hansen. “Evidence for a Multistep Pathogenesis of Chronic Myelogenous Leukemia.” Blood 58 (1981): 158–163.

  Gilliland, Gary D. “Nonrandom X-Inactivation Patterns in Normal Females: Lyonization Ratios Vary with Age.” Blood 88, no. 1 (1996): 59–65.

  Raza, Azra. “Consilence Across Evolving Dysplasias Affecting Myeloid, Cervical, Esophageal, Gastric and Liver Cells: Common Themes and Emerging Patterns.” Leukemia Research 24, no. 1 (2000): 63–72.

  CHAPTER 3: LADY N.

  Montoro, Julia, Aslihan Yerlikaya, Abdullah Ali, and Azra Raza. “Improving Treatment for Myelodysplastic Syndromes Patients.” Current Treatment Options in Oncology 19 (2018): 66. https://doi.org/10.1007/s11864-018-0583-4.

  Fuchs, Ota, ed. Recent Developments in Myelodysplastic Syndromes. London: IntechOpen, 2019. doi:10.5772/intechopen.73936.

  Platzbecker, U. “Treatment of MDS.” Blood 133, no. 10 (2019): 1096–1107.

  Ferrara. F., and O. Vitagliano. “Induction Therapy in Acute Myeloid Leukemia: Is It Time to Put Aside Standard 3 + 7?” Hematological Oncology (2019). doi:10.1002/hon.2615.

  Cerrano, M., and R. Itzykson. “New Treatment Options for Acute Myeloid Leukemia in 2019.” Current Oncology Reports 21, no. 2 (2019): 16. doi: 10.1007/s11912-019-0764-8.

  Buccisano, F. “The Emerging Role of Measurable Residual Disease Detection in AML in Morphologic Remission.” Seminars in Hematology 56, no. 2 (2019): 125–130. doi:10.1053/j.seminhematol.2018.09.001.

  Almeida, A., P. Fenaux, A. F. List, A. Raza, U. Platzbecker, and V. Santini. “Recent Advances in the Treatment of Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS).” Leukemia Research 52 (2017): 50–57. doi:10.1016/j.leukres.2016.11.008.

  “Luspatercept—Acceleron Pharma/Celgene Corporation.” Adis Insight. https://adisinsight.springer.com/drugs/800029519.

  Fenaux, P. “Luspatercept for the Treatment of Anemia in Myelodysplastic Syndromes and Primary Myelofibrosis.” Blood 133, no. 8 (2019): 790–794. doi:10.1182/blood-2018-11-876888.

  Prasad, Vinay. “Do Cancer Drugs Improve Survival or Quality of Life?” BMJ 359 (2017). https://doi.org/10.1136/bmj.j4528.

  Prasad, Vinay, et al. “The High Price of Anticancer Drugs: Origins, Implications, Barriers, Solutions.” Nature Reviews Clinical Oncology 14 (2017): 381–390. www.nature.com/articles/nrclinonc.2017.31.

  Keshavan, Meghana. “Did He Really Just Tweet That? Dr. Vinay Prasad Takes on Big Pharma, Big Medicine, and His Own Colleagues—With Glee.” Stat, September 15, 2017.

  “Exceptional Responders: Why Do Some Cancer Drugs Work for Them and Not Others?” Cancer Treatment Centers of America, March 8, 2018. www.cancercenter.com/community/blog/2018/03/why-do-some-cancer-drugs-work-for-them-and-not-others.

  Milowsky, M. I., et al. “Phase II Study of Everolimus in Metastatic Urothelial Cancer.” BJU International 112, no. 4 (2013): 462–470.

  “NCI Sponsored Trials in Precision Medicine.” Division of Cancer Treatment and Diagnosis. https://dctd.cancer.gov/majorinitiatives/NCI-sponsored_trials_in_precision_medicine.htm#h06.

  West, Howard. “Novel Precision Medicine Trial Designs Umbrellas and Baskets.” JAMA Oncology 3, no. 3 (2017): 423. doi:10.1001/jamaoncol.2016.5299.

  Marquart, John, et al. “Estimation of the Percentage of US Patients with Cancer Who Benefit from Genome-Driven Oncology.” JAMA Oncology 4, no. 8 (2018): 1093–1098. doi:10.1001/jamaoncol.2018.1660.

  Prasad, Vinay. “Perspective: The Precision-Oncology Illusion.” Nature 537 (2016): S63.

  Kaiser, Jocelyn. “A Cancer Drug Tailored to Your Tumor? Experts Trade Barbs over ‘Precision Oncology.’” Science, April 24, 2018. doi:10.1126/science.aat9794.

  Harris, Lyndsay, et al. “Update on the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH/EAY131) Precision Medicine Trial.” Pharmacogenetics, Pharmacogenomics, and Therapeutic Response 17, supplement 1 (2018). doi:10.1158/1535-7163.TARG-17-B080.

  Davis, C., et al. “Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals, 2009–13.” BMJ 359 (2017). https://doi.org/10.1136/bmj.j4530.

  Drilon, A., T. W. Laetsch, S. Kummar, et al. “Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children.” New England Journal of Medicine 378 (2018): 731–739. doi:10.1056/NEJMoa1714448.

  Broderick, Jason M. “FDA Approves Larotrectinib for NTRK+ Cancers.” OncLive, November 26, 2018. www.onclive.com/web-exclusives/fda-approves-larotrectinib-for-ntrk-cancers.

  Darwin, Charles. On the Origin of Species. Digireads.com.

  Nowell, P. C. “The Clonal Evolution of Tumor Cell Populations.” Science 194, no. 4260 (1976): 23–28.

  Greaves, Mel, and Carlo C. Maley. “Clonal Evolution in Cancer.” Nature 481 (2012): 306–313.

  Janiszewska, Michalina, et al. “Clonal Evolution in Cancer: A Tale of Twisted Twines.” Cell Stem Cell 16 (2015). https://doi.org/10.1016/j.stem.2014.12.011.

  McGranahan, Nicholas, and Charles Swanton. “Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.” Cell 168, no. 4 (2017): 613–628.

  Fidler, Isaiah J. “The Pathogenesis of Cancer Metastasis: The ‘Seed and Soil’ Hypothesis Revisited.” Nature Reviews Cancer 3 (2003): 453–458.

  Ribatti, D., et al. “Stephen Paget and the ‘Seed and Soil’ Theory of Metastatic Dissemination.” Clinical and Experimental Medicine 6, no. 4 (2006): 145–149.

  Fidler, Isiah J., et al. “The ‘Seed and Soil’ Hypothesis Revisited.” Lancet Oncology 9, no. 8 (2008): 808.

 
Pienta, Ken, et al. “The Cancer Diaspora: Metastasis Beyond the Seed and Soil Hypothesis.” Clinical Cancer Research 19, no. 21 (2013). doi:10.1158/1078-0432.CCR-13-2158.

  Tiong, Ing S., et al. “New Drugs Creating New Challenges in Acute Myeloid Leukemia.” Genes, Chromosomes & Cancer (2019). https://doi.org/10.1002/gcc.22750.

  Kubal, Timothy Edward, et al. “Safety and Feasibility of Outpatient Induction Chemotherapy with CPX-351 in Selected Older Adult Patients with Newly Diagnosed AML.” Journal of Clinical Oncology 36, supplement 15 (2018): e19013.https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e19013.

  Levis, Mark. “Midostaurin Approved for FLT3-Mutated AML.” Blood 129 (2017): 3403–3406.

  CHAPTER 4: KITTY C.

  Profiles in Science. The Mary Lasker papers. US National Library of Medicine.

  Wallace, Langley Grace. “Catalyst for the National Cancer Act: Mary Lasker.” Albert and Mary Lasker Foundation. December 15, 2016. www.laskerfoundation.org/new-noteworthy/articles/catalyst-national-cancer-act-mary-lasker/.

  “National Cancer Act of 1971.” National Cancer Institute. https://dtp.cancer.gov/timeline/noflash/milestones/M4_Nixon.htm.

  Holford, T. R. “Tobacco Control and the Reduction in Smoking-Related Premature Deaths in the United States, 1964–2012.” JAMA 311, no. 2 (2014): 164–171. doi:10.1001/jama.2013.285112.

  Kolata, Gina. “Advances Elusive in the Drive to Cure Cancer.” New York Times, April 23, 2009.

  Leaf, Clifton. The Truth in Small Doses: Why We’re Losing the War on Cancer—And How to Win. New York: Simon & Schuster, 2013.

  Baker, Monya. “1,500 Scientists Lift the Lid on Reproducibility: Survey Sheds Light on the ‘Crisis’ Rocking Research.” Nature 533 (2016): 452–454. www.nature.com/news/1-500-scientists-lift-the-lid-on-reproducibility-1.19970.

  DeVita, Vincent T., Jr., and Edward Chu. “A History of Cancer Chemotherapy.” Cancer Research 68, no. 21 (2008). doi:10.1158/0008-5472.CAN-07-6611.

  Gilligan, A. M. “Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer.” American Journal of Medicine 131, no. 10 (2018): 1187–1199.

 

‹ Prev